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Background
Mantle cell lymphoma is a clinically heterogeneous disease characterized by overexpression of
cyclin D1 protein. Blastoid morphology, high proliferation, and secondary genetic aberrations
are markers of aggressive behavior. Expression profiling of mantle cell lymphoma revealed that
predominance of the 3'UTR-deficient, short cyclin D1 mRNA isoform was associated with
high cyclin D1 levels, a high “proliferation signature” and poor prognosis.  
Design and Methods
Sixty-two cases of mantle cell lymphoma were analyzed for cyclin D1 mRNA isoforms and
total cyclin D1 levels by real-time reverse transcriptase polymerase chain reaction, and TP53
alterations were assessed by immunohistochemistry and molecular analysis. Results were cor-
related with proliferation index and clinical outcome.  
Results
Predominance of the short cyclin D1 mRNA was found in 14 (23%) samples, including four
with complete loss of the standard transcript. TP53 alterations were found in 15 (24%) cases.
Predominance of 3'UTR-deficient mRNA was significantly associated with high cyclin D1
mRNA levels (P=0.009) and more commonly found in blastoid mantle cell lymphoma (5/11,
P=0.060) and cases with a proliferation index of >20% (P=0.026). Both blastoid morphology
(11/11, P<0.001) and TP53 alterations (15/15, P<0.001) were significantly correlated with a high
proliferation index. A proliferation index of 10% was determined to be a significant threshold
for survival in multivariate analysis (P=0.01).
Conclusions
TP53 alterations are strongly associated with a high proliferation index and aggressive behavior
in mantle cell lymphoma. Predominance of the 3'UTR-deficient transcript correlates with high-
er cyclin D1 levels and may be a secondary contributing factor to high proliferation, but failed
to reach prognostic significance in this study.
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Introduction
Mantle cell lymphoma (MCL) is an aggressive B-cell lym-
phoma genetically characterized by the t(11;14)(q13;q32)
translocation leading to overexpression of cyclin D1
(CyD1), which is not normally expressed in lymphoid
cells.1,2 Although aberrant expression of CyD1 is seen in
almost 100% of MCL and a subset of other B-cell neo-
plasms, including 40% of multiple myelomas and hairy cell
leukemias due to various mechanisms,3,4 the precise role of
CyD1 overexpression in lymphomagenesis is still elusive.
D-type cyclins, which act as growth factor sensors, are not
per se sufficient to keep cells in cycle and need the cooper-
ation of other oncogenes to induce malignant transforma-
tion.5-7
Although MCL is a quite homogenous disease based on
phenotype and gene expression profile, the clinical course
of MCL is highly variable, with survival times ranging from
a few months to several years. Various studies have tried to
identify prognostic markers that predict the clinical course
and are able to distinguish aggressive variants from indo-
lent MCL. Alterations in cell cycle regulators, including
p53, CDK4 and p16/CDKN2, and DNA damage response
pathways have been found to be associated with high pro-
liferation index and aggressive clinical behavior.8-12 In par-
ticular, cases of MCL with inactivating TP53 mutations
have a significantly shorter median survival compared to
cases with wild-type TP53.9,11,13
The clinically aggressive blastoid variant of MCL, charac-
terized by either lymphoblast-like or large cells (pleomor-
phic type), shows a higher frequency of these additional
genetic aberrations, such as abnormalities of C-MYC,
TP53, p16/CDKN2 and p14ARF, as well as, the common
occurrence of hyperploidy or tetraploidy.14,15
Using global gene expression profiling, it was shown that
MCL cases predominantly or exclusively expressing a short
3’UTR-deficient CyD1 mRNA isoform have higher CyD1
mRNA levels, a higher “proliferation signature” and a sig-
nificantly poorer survival than cases which express the
standard full-length transcript.16 The long 3’UTR contains
AU-rich mRNA destabilizing elements, and the 3’UTR-
deficient mRNA is thought to exhibit increased stability. In
addition, the 3’UTR is targeted by microRNA (miRNA) of
the miR-15/16 family and the miR17-92 cluster, indirectly
reducing CyD1 protein.17 Loss of 3’UTR can be caused by
genomic deletion or rearrangement of the region encoding
the 3’UTR, or through mutations in the 3’UTR, which
introduce alternative polyadenylation signal sites.18,19
Although the proliferation signature was suggested to
represent an integrated measurement of different onco-
genic events targeting the cell cycle in MCL, it was not cor-
related with the proliferation index as assessed by Ki-67
immunostaining, a conventional examination available in
all pathology departments.16 Nonetheless, other studies
using Ki-67 staining have confirmed that the proliferation
index is one of the best prognostic indicators for MCL,
even in the context of different novel therapy regimes.20,21
To date, no systematic correlative analysis of CyD1 mRNA
isoform expression, alterations of TP53, and cell prolifera-
tion as determined by Ki-67 staining has been performed in
MCL. The aim of our study was, therefore, to clarify the
relationship and relative importance of total CyD1 expres-
sion, CyD1 isoform expression, genomic loss of the 3’
UTR, and p53 abnormalities with the proliferation index,
and morphological subtypes of MCL.
Design and Methods
Case selection
Paraffin-embedded blocks from 62 patients with CyD1-positive
MCL obtained at primary diagnosis were selected from the
archives of the Institute of Pathology, Technical University of
Munich, Germany and from the Tour de Pathologie, Liege,
Belgium. Additional samples from sequential biopsies taken 7
months to 6 years later were available for four patients. Reactive
lymph nodes and small intestinal mucosa samples were used as
controls for quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR) and fluorescent in situ hybridization (FISH)
analysis. The diagnosis of MCL was based on morphological and
immunophenotypic findings according to the World Health
Organization (WHO) classification of Neoplastic Diseases of
Hematopoietic and Lymphoid Tissue.22 The diagnosis of the mor-
phological MCL subtype was based on cell morphology and blind-
ly reviewed twice by two of the authors (LQ-M and FF). If discrep-
ancies arose, the cases were discussed to achieve consensus. CyD1
positivity was confirmed by immunohistochemistry in all cases.
The study was approved by the local ethics committee.
Immunohistochemical analysis 
Immunohistochemistry for CyD1, Ki-67 (clone MIB-1) and p53
was performed on an automated immunostainer (Ventana
Medical Systems, Inc., Tucson, AZ, USA) according to previously
published procedures.23 CyD1 (rabbit monoclonal SP4), Ki-67 and
p53 (DO-7 clone) antibodies were obtained from Dako
(Copenhagen, Denmark). Appropriate positive controls were used
to confirm the adequacy of the staining. The proliferation index
was assessed by counting at least 300 tumor cells on Ki-67-stained
sections, following the recommendations recently described in a
consensus paper.24 The results were given as percentages of total
tumor cells.24 If >30% of neoplastic cells showed Ki-67-positivity,
the case was defined as highly proliferative. In addition Ki-67-
positivity of 11-30% and 0-10% was defined as medium and low
proliferation, respectively. Cases were evaluated as p53-positive if
at least 20% of cells showed strong nuclear positivity. All p53-pos-
itive cases were screened for p53 mutations (see below). 
Analysis of total cyclin D1 and cyclin D1
isoform expression
To measure total CyD1 mRNA expression levels and CyD1
mRNA isoforms, real-time qRT-PCR was performed. Total RNA
was obtained from formalin-fixed, paraffin-embedded tissues and
was either isolated from entire sections or after macro-dissection,
to enrich the neoplastic population in cases with an irregular pat-
tern of infiltration. RNA isolation, DNase digestion and cDNA
synthesis were performed as described previously.25,26 Total CyD1
expression levels were given relative to the housekeeping gene
TATA box binding protein (TBP). The cut-off for total CyD1
mRNA was set at 8.6, defined as the mean ratio of CyD1/TBP +
three standard deviations (SD) for the normal lymphoid control
samples. Expression levels of CyD1 mRNA isoforms were deter-
mined using two different qRT-PCR assays, one spanning the
exon 1-2 junction (CyD1 total assay) and the other located in the
proximal 3’UTR (CyD1 3’UTR assay). The amount of short CyD1
isoform was calculated by the DDCt method.25,27 Reactive lym-
phoid tissue was used as the control for background CyD1 levels,
and small intestinal samples, which show higher physiological
CyD1 expression, served as a control to assess the normal range of
the CyD1 isoform ratio (CyD1 isoform ratio=2-DDCt, DDCt=[Ct-
value CyD1 3’UTR(tumor)–Ct-value CyD1 total(tumor)]-[(mean
Ct-value CyD1 3’UTR(controls) – (mean Ct-value CyD1 total
(controls)]. A ratio (proximal 3’UTR/exon1-2) of 0.6 or lower was
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regarded as evidence of significant expression of the short
D3’UTR-deficient CyD1 isoform. No RT controls were used to
control for DNA contamination in the 3’UTR assay. The
sequences for primers and probes (CyD1 total, CyD1 3’UTR and
TBP) used in the study have been published previously.27 Using
300 nmol/L of primers and 200 nmol/L of the corresponding
probes, we obtained very similar amplification efficiencies of
3’UTR amplicons in relation to the exon 1-2 junction, allowing
direct gene dosage estimation without using calibration stan-
dards.28 TaqMan assays were performed in duplicate using the ABI
PRISM 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA).
Cyclin D1 3’UTR genomic deletion 
Genomic DNA was obtained from 62 MCL cases and extract-
ed either from entire or macrodissected sections, as described
above. At least three replicates of 40 ng genomic DNA were
subjected to qRT-PCR analysis to study CyD1 3’UTR gene
dosage. The primers and probe sequences for the CyD1 3’UTR
region were identical to those used for the expression analysis.
Since MCL commonly shows complex karyotypes with aneu-
ploidy or tetraploidy, we used several genomic regions on dif-
ferent chromosomes as endogenous controls, including Beta-glo-
bin, SOCS 1, Beta-2-microglobulin and Albumin, as described pre-
viously.27 For each sample, CyD1 3’UTRwas compared to these
endogenous control genes, using normal lymphoid tissues as
reference. We obtained very similar amplification efficiencies of
3’UTR genomic amplicons in relation to endogenous controls,
allowing direct gene dosage estimation without using calibra-
tion standards.28
Mutation analysis
Screening for mutations of exons 5 to 8 of the TP53 gene,
including the intron/exon boundaries, was performed in a subset
of MCL cases by denaturing high performance liquid chromatog-
raphy (DHPLC) on an automated DHPLC analysis system (WAVE,
Transgenomic, Omaha, NE, USA) as described previously.29
Chromatograms were read manually and evaluated independently
by three observers (GK, JSH and LQM). All PCR products showing
suspicious chromatograms were subjected to direct sequencing
analysis. 
Exons 4 and 5 of the CCND1 gene, including the proximal
CyD1 3’UTR region, were sequenced in cases with predominant
expression of the short CyD1 mRNA variant, as previously
described.27 Automated fluorescent sequencing was performed
with the BigDye Terminator Cycle Sequencing kit (PE Applied
Biosystems, Foster City, CA, USA) and ABI Prism 377 automated
sequencer (PE Applied Biosystems). Comparison with the wild-
type sequences was performed with DNASIS 2.6 software
(Hitachi Software Engineering, Yokohama, Japan).
CCND1/cyclin D1 gene analysis by fluorescent in situ
hybridization
FISH analysis was performed using the commercially available
LSI IgH/CCND1 and LSI Cyclin D1/CEP 11 probes according to
previously published procedures.30 Probes were purchased from
Vysis (Vysis Inc, Downers Grove, IL, USA) and used according to
the manufacturer’s instructions. The nuclei were counterstained
with Hoechst 33342 (Molecular Probes, Leiden) and slides were
mounted with Vectashield medium (Vector Laboratories, USA).
Imaging was performed with a LSM-510 NLO laser microscope
(Zeiss, Jena, Germany). Image processing was carried out with
Zeiss computer software (AIM 3.2). Control specimens were pre-
pared from reactive lymph nodes to determine cut-off levels for
aberrant signals. 
Follow-up
The patients were followed up for a range of 1-105 months.
Data were collected from at least one of the following sources: the
hospitals’ inpatient and outpatient records (periodically reviewed
for updated information), primary physicians’ offices, and direct
contact with the patient or family. The primary endpoint was
overall survival duration from the date of MCL diagnosis to the
date of death. Patients who were alive at the end of the study peri-
od were censored on the last date of follow-up. The end of the
observation period was the end of April 2011. 
Statistical analysis
SPSS statistical software (SPSS Inc., Chicago IL, USA) was used
for the statistical analyses. Associations in 2 × 2 tables were eval-
uated with Fisher's exact test. Correlations were assessed by
Pearson’s or Spearman’s correlation analysis. Continuous variables
between different groups were compared using the Mann-
Whitney U test. Survival was analyzed using Kaplan-Meier esti-
mates and the curves were compared by the log-rank test. P levels
<0.05 were considered statistically significant. In addition, maxi-
mally selected log-rank statistics were used to determine the opti-
mal cut-off for proliferation. To consider multiple testing in this
setting, the R-function ‘maxstat.test’ was employed.
Results
Clinico-pathological features and proliferation index
Of the 62 patients included in the study, 42 were males and 14
females, with a median age of 67 years at diagnosis (range, 34 to
89 years). No personal data were available for six patients. Follow-
up information was obtained from the medical records for 51
patients (38 males and 13 females). Most tissue samples were
lymph nodes biopsies (n=44), whereas the remainder were
derived from various extranodal sites (ten from the naso- and
oropharynx, four from soft tissue, three from the intestine and one
from prostate). All cases showed strong CyD1 immunostaining
and a phenotype and morphology consistent with MCL. Fifty-one
(82%) of 62 cases were classified as classical and 11/62 (18%) as
blastoid subtype of MCL, including two pleomorphic variants
(Figure 1). Among the four patients with classical MCL for whom
sequential biopsies were available, blastoid transformation was
evident in one case (#21) after a period of 16 months, accompanied
by an increase of proliferation index from 3% to 26% (Ki-67). The
median proliferation index, as assessed by Ki-67 staining, was
15%, ranging from 1% to 100% of tumor cells (Figure 1). The high
proliferation group included 19 MCL cases (31%), the medium
proliferation group contained 17 cases (27%), and the low prolif-
eration group contained 26 cases (42%), with a median prolifera-
tion index of 36%, 21% and 7%, respectively. All 11 cases (100%)
of blastoid MCL were in the high proliferative group as opposed
to 8/51 (16%) of the classic variant (P<0.001) (Figure 2A).
Cyclin D1 mRNA isoform expression and cyclin D1
3’UTR alterations 
Total CyD1 mRNA expression levels in MCL samples ranged
widely from 9 to 215 (median CyD1/TBP=56). The long standard
CyD1 transcript was the predominant isoform expressed in 48/62
MCL cases (77%). These cases expressed only low levels of the
short D3’UTR mRNA. In contrast, 14 MCL cases (23%) predomi-
nantly expressed the short D3’UTR CyD1 mRNA, indicated by a
3’UTR/exon1-2 ratio of less than 0.6, including four cases (6%)
with a complete loss of the 3’UTR of CyD1 mRNA. In order to
investigate the cause of complete loss of the 3’UTR of CyD1
mRNA, quantitative genomic PCR was performed. Two of the
J. Slotta-Huspenina et al.
1424 haematologica | 2012; 97(9)
©F
err
ata
 S
t r
ti F
un
da
tio
n
four cases showed genomic deletion of the 3’UTR locus whereas
in the remaining two cases, neither deletions nor mutations of
exons 4 and 5 including the 3’UTR were found. The 14 MCL cases
with predominant expression of the D3’UTR CyD1 isoform
showed significantly higher total CyD1 mRNA expression levels
than the MCL cases with the long standard transcript (median
CyD1/TBP ratio 93 versus 50, interquartile range (IQR) 56-117 ver-
sus 29-79, P=0.009). The two MCL cases with genomic 3’UTR
deletion had total CyD1 levels of 95.3 and 68.3 and did not differ
from other MCL cases with predominance of the short CyD1 iso-
form. The sequential samples from four MCL patients showed
similar CyD1 mRNA levels and CyD1 mRNA isoform expression.
p53 overexpression and TP53 mutational analysis
p53 overexpression was observed in 13 (21%) of 62 MCL cases;
eight cases had blastoid morphology (8/11; 73%) and five cases
corresponded to the classical MCL variant (5/51; 10%). Ten of
these 13 cases showed p53 overexpression in more than 50% of
the tumor cells (Figure 1). To complete the TP53 status analysis,
mutational screening of exons 5 to 8 of the TP53 gene was per-
formed by DHPLC followed by sequence analysis in MCL cases
with a proliferation index >30% for which enough DNA was
available (seven blastoid and five classical MCL). These cases
included eight p53-positive cases and four p53-negative cases. In
six cases with p53 overexpression and in two highly proliferative
cases negative for p53 by immunohistochemistry, missense muta-
tions leading to amino acid substitutions were detected (five in
exon 5 and one each in exon 6, exon 7 and exon 8). In the remain-
ing two p53-positive cases DHPLC analysis showed an abnormal
DHPLC pattern suggestive of mutations, one in exon 6 and one in
exon 8, but not enough DNA was available for sequence analysis
(Table 1). As a control, mutational screening of exons 5 to 8 of the
TP53 gene was performed by DHPLC in 16 MCL negative for p53
and with a proliferation index <30%. In all cases normal patterns,
indicative of wild-type TP53, were observed. In summary,
p53/TP53 alterations were found in 15 MCL cases, ten with blas-
toid morphology and five with classical morphology.
Correlation between proliferation index  
and histological subtype, cyclin D1 expression levels
and p53 alterations 
The correlations between histological subtype, CyD1 isoform
expression, p53 alterations and the proliferation index are illustrat-
ed in Figures 2 and 3. Median proliferation indices were 40% ver-
sus 10% in blastoid versus classical cases (IQR 50-32 versus 22-7,
P<0.001), 30% versus 13% in cases with D3’UTR CyD1 versus stan-
dard CyD1 (IQR 36-10 versus 30-7, P=0.11) and 37% versus 10% in
MCL cases with p53 alterations versus wild-type p53 (IQR 50-33
versus 21-7, P<0.001). All cases with blastoid morphology (11/11,
100%) showed a high proliferation index (median MIB1=40%,
IQR 32-50%) whereas only eight of the cases with classical mor-
phology (8/51, 16%) belonged to the high proliferation group
Cyclin D1 mRNA isoforms and p53 in MCL
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Figure 1. Blastoid (A, C, E) and classic MCL (B, D). (A) Blastoid MCL
shows large tumor cells with irregular large nuclei with open chro-
matin and a high mitotic rate (original magnification 400x) (C) MIB1
staining shows 80% positive tumor cells (case 3, original magnifica-
tion 200x) (E) Virtually all tumor cells show strong expression of p53
protein (case 49, original magnification 200x) (B) Classical MCL
shows cells with scant cytoplasm and small irregular nuclei (original
magnification 400x) (D) MIB1 shows nuclear positivity in 13% of
tumor cells (case 42, original magnification 200x).
Figure 2. Scatter plots show the correlation between (A) proliferation
index and blastoid morphology, (B) proliferation, morphological sub-
type and CyD1 isoform expression (red diamonds: predominant
D3’UTR expression) and (C) proliferation, morphological subtype and
p53 alteration (yellow diamonds: p53 overexpression/mutation).
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(median MIB1=35%, P<0.001). Total CyD1 expression levels did
not differ significantly between high, medium and low prolifera-
tion groups (median CyD1/TBP: 68 versus 83 versus 51, IQR 37-95
versus 36-107 versus 28-63, P=0.116), but there was a tendency for
cases with predominant D3’UTR CyD1 mRNA to be more fre-
quently found in the group with blastoid morphology (5/11) than
in the classical subtype (9/51) (P=0.060) (Figure 2B). Although,
total CyD1 levels were higher in blastoid MCL than in the classical
MCL subtype, the difference was not statistically significant
(median CyD1/TBP 68 versus 53, IQR 44-115 versus 32-85,
P=0.253). MCL cases with predominant D3’UTR CyD1 mRNA
were found in the high, medium and low proliferation groups
(7/19=37% versus 3/17=18% versus 4/26=15%, P=0.20) with over-
representation in the highly proliferative group. However, only if
a Ki67 index of 20% was used as a single cut-off were both total
CyD1mRNA levels (P=0.022) and D3’UTR CyD1 mRNA
(P=0.026) significantly associated with high proliferation.
Complete 3’UTR loss at the mRNA level, as well as, genomic
3’UTR deletion were found in both morphological subtypes.
Alterations of p53/TP53 (overexpression and/or mutations) were
found exclusively in the highly proliferative group (15/19), but in
none of the MCL cases with medium or low proliferation index
J. Slotta-Huspenina et al.
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Table 1. Clinicopathological features of highly proliferative mantle cell lymphomas.
Case Age Sex Histology P53 (%) P53 Ki-67 CycD1 mRNA CycD1 mRNA 11q13/ CCND1 Follow-up
(mutation analysis) (%) (D1/TBP) transcript
49 57 M blastoid 100 ND 100 68.3 excl. D 3'UTR trisomy/ del 3´UTR DwD, 10 mo
3 67 F blastoid >80 c.818G>T,p.Arg273Leu 80 210.2 standard polysomy DwD, 4 mo
(exon 8)
4 76 M blastoid <5 c.404G>A,p.Cys135Tyr 50 95.1 standard ND DwD, 34 mo
(exon 5)
38 52 M blastoid <5 c.727A>G,p.Met243Val 47 28.7 standard trisomy LFU
(exon 7)
7 66 M blastoid 20-30 DHPLC  (exon 6) 46 131.7 standard tetrasomy DwD, 14 mo
12 61 M blastoid >80 c.659A>G,p.Tyr220Cys 40 59.0 D 3'UTR trisomy/ normal DwD, 38 mo
(exon 6)
44 78 M blastoid >80 ND 37 55.4 D 3'UTR disomy/ normal AwD, 105 mo
9 64 M blastoid >80 c.16-376_379delTACT, 36 94.4 D 3'UTR tetrasomy/ normal DwD, 11 mo
p.Thr125fs (exon5)
1 71 F blastoid >80 ND 32 43.5 standard disomy DwD, 33 mo
63 67 M blastoid 20 c.469G>T,p.Val157Phe 31 115.1 D 3'UTR trisomy/ normal DwD, 4 mo
(exon 5)
5 66 M blastoid <5 ND 31 12.6 standard ND AwD, 80 mo
53 71 M classic 60 c.537T>G,p.His179Gln 75 78.4 standard trisomy DwD, 24 mo
(exon 5)
41 68 F classic <5 wt 45 36.8 standard ND DwD, 23 mo
47 57 M classic >80 C536A>G,p.His179Arg 35 56.1 D 3'UTR disomy/ normal DwD, 16 mo
(exon 5)
56 89 F classic 20-30 DHPLC  (exon 8) 35 31.8 standard trisomy DwD, 12 mo
40 50 M classic >60 ND 33 19.1 standard disomy DwD, 12 mo
45 72 M classic >80 ND 31 70.3 standard ND DwD, 18 mo
26 56 M classic <5 wt 35 73.0 standard ND DwD, 15 mo
35 65 M classic <5 ND 32 103.1 excl. D 3'UTR disomy/ normal LFU
excl.: exclusive; DwD: died with disease; AwD: alive with disease; LFU: lost to follow-up; DHPLC: denaturing high performance liquid chromatography; ND: not done; wt: wild-type.
Table 2. Uni- and multivariate analyses of effects of prognostic factors on overall survival.
Multivariate Analysis Univariate analysis
Characteristic Hazard ratio 95%CI P value Hazard ratio 95%CI P value
Morphology (blastoid vs. classical) 0.901 0.405-2.003 0.795 2.934 0.949-9.078 0.062
TP53 alteration vs.WT 0.487 0.241-0.985 0.039 0.438 0.165-1.164 0.098
D3’UTR vs. standard CyD1 0.894 0.385-2.072 0.791 1.105 0.389-3.139 0.851
Proliferation (<10%, 10-29%, ≥30%)
medium vs. high 0.810 0.358-1.833
0.035
low vs. high 0.422 0.187-0.955
Proliferation (MIB1 ≥10% vs. 0-9%) 2.569 1.223-5.400 0.010 2.912 1.156-7.336 0.023
CI: confidence interval.
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(0/43) (P<0.001). Similarly, ten (91%) of the 11 blastoid MCL cases
showed alterations of TP53, whereas only five (10%) of the 51
typical MCL cases (10%) did (P<0.001). p53 alterations remained
highly statistically significant when cases were separated into two
groups, irrespective of the cut-off points for proliferation (10%,
20%, or 30%). Of interest, the MCL case with the highest prolif-
eration index of 100% showed both strong nuclear p53 positivity
in >90% of the tumor cells and predominance of the D3’UTR tran-
script.
The characteristics of the highly proliferative cases are summa-
rized in Table 1. Concurrent predominant expression of short
DCyD1 isoform and p53/TP53 alterations was observed in six
cases, p53/TP53 alterations alone in nine cases and D3’UTR CyD1
expression without evidence of TP53 alterations was observed in
one case, whereas neither was present in the remaining three
cases. Thus, in the high proliferation group, all but one of the cases
with predominance of the D3’UTR CyD1 mRNA additionally
showed overexpression and/or mutation of p53. However, there
were no significant differences in the proliferation index irrespec-
tive of whether none, any or both of the above features were pres-
ent in the tumor cells.
Survival
Follow-up data were available for 51 patients. Thirty-five
patients (69%) died of progressive disease with a mean period
from the date of diagnosis to death of 39.8 months (range, 1-97
months). Sixteen patients are still alive with disease (follow-up
period from 2-105 months). Univariate analysis of the prognostic
significance of the different parameters was performed for overall
survival by the Kaplan-Meier method (Figure 4). Using the
described cut-offs, overall survival differed significantly between
the three proliferation groups with a median survival time of 16
months in the high proliferation group (n=17), 21 months in the
medium (n=12) and 58 months in the low proliferation group
(n=22) (P=0.035, Figure 4A). Notably, overall survival did not differ
between the medium and the high proliferation groups in our set
of cases. Using maximally selected log rank statistics, proliferation
was highly significant for overall survival in multivariate analysis
(P=0.023) with a determined optimal cut-off of 10% (Figure 4B).
Results of uni- and multivariate analyses are summarized in Table
2. Patients with p53 overexpression/TP53 alteration had a signifi-
cantly worse prognosis (median survival, 14 months) compared to
patients with wild-type p53 (median survival, 36 months)
(P=0.039, Figure 4C). In contrast, there was no statistically signifi-
cant influence of D3’UTR CyD1 expression on overall survival
(P=0.791, Figure 4D), as patients with the standard CyD1 isoform
had a median survival of 33 months compared to the 24 months
of patients with predominant D3’UTR transcript. In order to con-
trol for confounding factors, multivariate analysis was performed
after leaving out either Ki67 index or p53 alterations. In both
instances, proliferation and p53 (P=0.008), respectively, were high-
ly significant for overall survival, whereas CyD1 mRNA levels and
D3’UTR transcript were not. This indicates that p53 and prolifera-
tion index are interdependent factors concerning survival.
Discussion
The proliferation index is an important prognostic parameter in
MCL. The impact of different genetic alterations on proliferation
index has not yet been analyzed systematically, although several
secondary alterations associated with a poor prognosis have been
described. In this study, we demonstrate that alterations of the
TP53 tumor suppressor gene are strongly associated with a high
Ki67 index and blastoid morphology, representing major biological
determinants of aggressive behavior. Expression of the truncated
D3’UTR CyD1 mRNA variant was associated with higher CyD1
mRNA levels and occurred more often in cases with a proliferation
index >20%, but lacked independent prognostic significance.
MCL is an aggressive subtype of B-cell non-Hodgkin’s lym-
phoma with a median survival of 3-4 years with conventional
therapy. Nevertheless, the range of clinical behavior is broad, and
a subset of patients with indolent disease experience long-term
survival.2 A variety of tumor-related risk factors for poor outcome
have been identified, namely blastoid morphology and high pro-
liferation index, as assessed by MIB1 staining.20,21,31-34 Poor prog-
nostic features are commonly associated with alterations of TP53,
C-MYC and CDK4, indicating that secondary genetic events con-
tribute to the aggressive behavior of the lymphoma and may pro-
vide independent prognostic information.10-12,14,35 Whereas blastoid
MCL invariably has a high proliferation index, the growth fraction
of classical MCL shows a broad range, ranging from less than 5%
to more than 70% MIB-1-positive tumor cells. In our series, 16%
of classical MCL belonged to the highly proliferative group with
>30% MIB-1 positivity, similar to the findings of other authors.20,
21 Separating MCL according to growth fractions of <10%, 10-
29% and >30% discerned patients with median overall survivals
of 112, 59 and 30 months, respectively, in a large multicenter
study. The difference between these groups was preserved when
rituximab was part of the treatment regimen.20 The recognition of
the paramount importance of the proliferation index has led the
European MCL group to adopt guidelines for quantifying MIB1
staining in MCL, in order to increase reproducibility of the prolif-
eration index.24
A distinct approach for looking at prognostic markers in MCL
has been taken by Rosenwald et al.16 Using gene expression profil-
ing of a series of 92 CyD1-positive MCL, they identified a set of
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Figure 3. Relationship between p53 overexpression/ mutation, D3’UTR cyclin D1 isoform expression, blastoid morphology and the prolifera-
tion index measured by MIB-1 immunostaining. Sixty-two MCL cases are ordered by MIB1 positivity (1-100% from left to right). Red squares
in the upper three bars represent cases with p53 alteration, predominant D3’UTR cyclin D1 isoform expression and blastoid morphology,
respectively. 
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overexpressed genes involved in cell proliferation, the so-called
proliferation signature, which was strongly associated with poor
survival. Patients in the lowest quartile of the expression signature
had a median survival of 6.71 years, as compared to only 0.83
years of the patients in the highest quartile. Of interest, MCL cases
with a high proliferation signature and shorter disease-related sur-
vival were more likely to express, predominantly or exclusively,
the short isoform of CyD1 mRNA. Since cases with a truncated
CyD1 transcript showed higher levels of total CyD1 mRNA, and
mRNA and protein levels are closely correlated, the authors pos-
tulated that CyD1 level was a major determinant of the prolifera-
tion signature and, ultimately, prognosis, because of the crucial
role of CyD1 protein levels for cell cycle progression. 
The reasons for increased levels of CyD1 mRNA in cases with
predominance of the truncated variant probably lie in the destabi-
lizing function of the 3’UTR, which contains AU-rich elements,
which are crucial for regulating mRNA stability.36 Genes with long
3’UTR such as CyD1 usually encode for short-lived proteins
involved in proliferation and other tightly regulated, transient cel-
lular functions.37 In addition, truncation of the 3’UTR of the CyD1
mRNA results in loss of miR-16-1 binding sites and may change
regulation of CyD1 protein expression.38
Although the predominance of the short CyD1 isoform in MCL
is common – 23% in our series, similar to the 18% observed by
Wiestner et al. - the reasons for this are evident only in a minority
of cases.19 Only 6% of MCL lacked the long canonical transcript
completely, and in only half of these cases were we able to
demonstrate a genomic deletion of the 3’UTR explaining the com-
plete loss of expression. Since previously described mutations
introducing stop codons were not observed in our series,19 translo-
cations with rearrangement of the 3’UTR without loss of genomic
material (and, therefore, not detectable by q-PCR) or epigenetic
alterations might play a role in these cases.18
Another potential reason for a high percentage of short,
D3’UTR transcripts would be the predominant generation of the
CyD1b isoform, which lacks exon 5 and the conventional 3’UTR
region because of alternative splicing, supposedly due to a com-
mon splice site polymorphism A870G at the exon 4/intron 4
boundary.39,40 The protein encoded by this splice variant lacks
the PEST sequence important for protein turn-over, but retains
catalytic function and has been found to be potently transform-
ing in vitro.41,42 Despite the potentially increased oncogenicity of
this mRNA variant, we did not find any correlation between the
splice site A/G polymorphism and the percentage of CyD1b
transcript, which made up less than 10% of the total CyD1
mRNA in most studied cases, on the one hand, and levels of total
CyD1 mRNA or proliferation index on the other hand (data not
shown). More importantly, we failed to find a correlation
between the levels of the short CyD1 transcript and CyD1b
transcript. These negative results are in line with more recent
findings by several groups, which also failed to identify a major
role for the CyD1b transcript or the splice site polymorphism in
MCL.43-46
Irrespective of the reasons for the predominance of the D3’UTR
transcript, the initial finding of a correlation with high total CyD1
levels, high proliferation index and shorter survival induced us to
investigate the interplay between this and other known factors of
poor prognosis in more detail, given the paucity of comparative
data.47 Of note, Rosenwald et al. did not correlate their findings
with conventional assessment of MIB1/Ki67 staining.
Furthermore, they studied alterations of p53 only by quantitative
PCR, without mutational analysis or immunostaining, and failed
to identify a correlation between the proliferation signature and
p53 deletion.16 However, the high frequency of TP53 alterations in
J. Slotta-Huspenina et al.
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Figure 4. Overall survival analysis (Kaplan-
Meier curves) of 51 MCL patients. (A)
according to separation into three groups
with high (>30% MIB1-positivity), medium
(11-30% MIB1-positivity) and low prolifera-
tion index (0-10% MIB1-positivity), (B) sep-
aration into two groups with a cut-off of
10% as determined by maximally selected
log-rank statistics (C) according to p53 sta-
tus and (D) according to predominant
cyclin D1 (CyD1) isoform expression.  
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highly proliferative cases including the blastoid variant in our
study is not surprising and confirms previous findings, which
clearly indicate that further perturbations of cell cycle regulatory
mechanisms are necessary for uncontrolled proliferation.10-12,14,35
TP53 gene mutations in lymphoid neoplasms have been associat-
ed with progression, high grade transformation and poor progno-
sis. In MCL TP53mutations/deletions and p53 overexpression are
frequently detected in the terminal leukemic phase and may be
among the mechanisms involved in the development of aggressive
forms of this lymphoma.9,11,13,48-50
The role of CyD1, which acts as a growth factor sensor under
physiological circumstances, in the oncogenesis of B-cell neo-
plasms is far from clear. Both observations in human tumors as
well as in CyD1-transgenic animals indicate that a simple mecha-
nistic model – high CyD1 levels result in increased proliferation –
is insufficient to explain aggressive behavior in MCL. In humans,
B-cell neoplasms with overexpression of CyD1 show a broad
spectrum of clinical behavior. In multiple myeloma (MM), we pre-
viously failed to identify a correlation between predominant
expression of the D3’UTR CyD1 and higher proliferation,
although t(11;14)-positive MM cases predominantly expressing
the truncated mRNA variant tended to show higher levels of total
CyD1 transcript, similar to MCL.27 A potential explanation for this
lack of correlation between CyD1 levels and proliferation in
t(11;14)-positive MM was proposed by Ely et al., who demonstrat-
ed that CyD1 alone is not sufficient to induce retinoblastoma pro-
tein phosphorylation and cell cycle progression in CyD1-positive
MM, unless CDK4 is also elevated.51 Of note, average CyD1
mRNA levels in t(11;14)-positive MM are significantly higher than
in MCL, probably because of the higher transcriptional activity of
the translocated IgH locus in neoplastic plasma cells.30,52 Hairy cell
leukemia, another B-cell non-Hodgkin’s lymphoma expressing
CyD1 due to an unknown mechanism, usually has a very low pro-
liferation index. Furthermore, the t(11;14) translocation is detected
in a significant number of cases of monoclonal gammopathy of
unknown significance without having a negative prognostic influ-
ence,53 and, recently, cases of in situ MCL with indolent behavior
have been observed.54
On the other hand, overexpression of CyD1 is unable to induce
B-cell lymphomas without the help of cooperating oncogenes in
transgenic mouse models. Furthermore, we have recently shown
that siRNA-mediated knockdown of CyD1 in MCL cell lines has
little influence on cell proliferation, because of a compensatory up-
regulation of cyclin D2.55
Despite this heterogeneous picture concerning the role of CyD1
in lymphoma and although both high total CyD1 mRNA levels
and predominance of the short mRNA transcript were found in all
proliferation groups, we did observe a significant correlation for
both parameters with a proliferation index >20%, and blastoid
MCL cases were more likely to express the truncated D3’UTR; a
phenomenon which has also been observed by others.56 However,
we failed to identify an association between high CyD1 levels or
D3’UTR transcript predominance and overall survival. This might
be due to the small cohort, or alternatively indicates that the
D3’UTR mRNA acts only as a secondary factor for proliferation.
Accordingly, concomitant occurrence of p53 alterations and short
CyD1 mRNA expression was common in highly proliferative
cases, which could indicate that these two phenomena can collab-
orate to induce an aggressive phenotype in MCL. Furthermore, it
should be pointed out that MIB1 staining and assessment of the
“proliferation signature” including CyD1 isoforms as one parame-
ter, as performed by Rosenwald et al., are two different approaches
to assess cell proliferation.
In summary, our data indicate that high CyD1 levels alone, irre-
spective of the causative mechanism, do not necessarily cause a
high proliferation index in MCL.  We also confirm that expression
of the short D3’UTR variant CyD1 transcript occurs in a significant
minority of cases of MCL, may be associated with genomic dele-
tions of the 3’UTR, and results on average in higher CyD1 mRNA
levels. Furthermore, the very high frequency of TP53 alterations in
MCL cases with a high Ki67 index and poor prognosis underlines
the importance of secondary genetic alterations in the further dis-
ruption of cell cycle control promoting high proliferation and an
aggressive clinical behavior. 
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